Skip to main content
SpringerLink
Log in

Medical treatment of hereditary neuropathies

  • Chapter
Hereditary Peripheral Neuropathies

  • 672 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The BDNF study group. (Phase 3) (1999) A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52:1427–1433

    Google Scholar 

  2. Bains JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev 25:335–358

    Article  PubMed  CAS  Google Scholar 

  3. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

    Article  PubMed  CAS  Google Scholar 

  4. Bella AJ, Brock GB (2003) Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep 4:472–478

    PubMed  Google Scholar 

  5. Bradbury J (2004) Antiprogesterone hope for inherited neuropathy. Lancet Neurol 3:6

    PubMed  Google Scholar 

  6. Carenini S, Maurer M, Werner A, Blazyca H, Toyka KV, Schmid CD, Raivich G, Martini R (2001) The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J Cell Biol 152:301–308

    Article  PubMed  CAS  Google Scholar 

  7. Carson CC, 3rd (2003) Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 4:488–496

    PubMed  Google Scholar 

  8. Coleman M, Perry V (2002) Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25:532

    Article  PubMed  CAS  Google Scholar 

  9. De Jonghe P, Timmerman V (2003) Anti-steroid takes aim at neuropathy. Nat Med 9:1457–1458

    PubMed  Google Scholar 

  10. Devroe E, Silver PA (2004) Therapeutic potential of retroviral RNAi vectors. Expert Opin Biol Ther 4:319–327

    Article  PubMed  CAS  Google Scholar 

  11. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA (2004) Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 61:160–173; quiz 175-166

    PubMed  CAS  Google Scholar 

  12. Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH (1982) Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc 57:239–246

    PubMed  CAS  Google Scholar 

  13. Fenton CF, 3rd, McGlamry ED, Perrone M (1982) Severe pes cavus deformity secondary to Charcot-Marie-Tooth disease: a case report. J Am Podiatry Assoc 72:171–175

    PubMed  Google Scholar 

  14. Fenton CF, 3rd, Schlefman BS, McGlamry ED (1984) Surgical considerations in the presence of Charcot-Marie-Tooth disease. J Am Podiatry Assoc 74:490–498

    PubMed  Google Scholar 

  15. Folkers K, Simonsen R (1995) Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1271:281–286

    PubMed  CAS  Google Scholar 

  16. Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S (1985) Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci U S A 82:4513–4516

    PubMed  CAS  Google Scholar 

  17. Frostick SP, Yin Q, Kemp GJ (1998) Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery 18:397–405

    PubMed  CAS  Google Scholar 

  18. Gould N (1984) Surgery in advanced Charcot-Marie-Tooth disease. Foot Ankle 4:267–273

    PubMed  CAS  Google Scholar 

  19. Guenard V, Schweitzer B, Flechsig E, Hemmi S, Martini R, Suter U, Schachner M (1999) Effective gene transfer of lacZ and P0 into Schwann cells of P0-deficient mice. Glia 25:165–178

    PubMed  CAS  Google Scholar 

  20. Hellstrom WJ (2003) Vardenafil: a new approach to the treatment of erectile dysfunction. Curr Urol Rep 4:479–487

    PubMed  Google Scholar 

  21. Low PA (2002) Autonomic neuropathies. Curr Opin Neurol 15:605–609

    Article  PubMed  Google Scholar 

  22. Lupski J, Wise C, Kuwano A, Pentao L, Parke J, Glaze D, Ledbetter D, Greenberg F, Patel P (1992) Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A. Nat Genet 1:29–33

    Article  PubMed  CAS  Google Scholar 

  23. Maier M, Berger P, Suter U (2002) Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease? J Anat 200:357–366

    Article  PubMed  Google Scholar 

  24. Martini R (2001) The effect of myelinating Schwann cells on axons. Muscle Nerve 24:456–466

    Article  PubMed  CAS  Google Scholar 

  25. Maurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R (2002) Role of immune cells in animal models for inherited neuropathies: facts and visions. J Anat 200:405–414

    Article  PubMed  Google Scholar 

  26. Naef R, Adlkofer K, Lescher B, Suter U (1997) Aberrant protein trafficking in Trembler suggests a disease mechanism for hereditary human peripheral neuropathies. Mol Cell Neurosci 9:13–25

    Article  PubMed  CAS  Google Scholar 

  27. Naef R, Suter U (1999) Impaired intracellular trafficking is a common disease mechanism of PMP22 point mutations in peripheral neuropathies. Neurobiol Dis 6:1–14

    Article  PubMed  CAS  Google Scholar 

  28. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV (2000) A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:201–206

    Article  PubMed  CAS  Google Scholar 

  29. Pappagallo M (2003) Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 25:2506–2538

    Article  PubMed  CAS  Google Scholar 

  30. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10:396–401

    Article  PubMed  CAS  Google Scholar 

  31. Perea J, Robertson A, Tolmachova T, Muddle J, King RH, Ponsford S, Thomas PK, Huxley C (2001) Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum Mol Genet 10:1007–1018

    Article  PubMed  CAS  Google Scholar 

  32. Rusciani L, Severino E, Rusciani A (2002) Type A botulinum toxin: a new treatment for axillary and palmar hyperhidrosis. J Drugs Dermatol 1:147–151

    PubMed  Google Scholar 

  33. Saifi GM, Szigeti K, Snipes GJ, Garcia CA, Lupski JR (2003) Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies. J Investig Med 51:261–283

    PubMed  CAS  Google Scholar 

  34. Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9:1533–1537

    Article  PubMed  CAS  Google Scholar 

  35. Wagey R, Lurot S, Perrelet D, Pelech SL, Sagot Y, Krieger C (2001) Phosphatidylinositol 3-kinase activity in murine motoneuron disease: the progressive motor neuropathy mouse. Neuroscience 103:257–266

    Article  PubMed  CAS  Google Scholar 

  36. Williams LL, O’Dougherty MM, Wright FS, Bobulski RJ, Horrocks LA (1986) Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease. Neurology 36:1200–1205

    PubMed  CAS  Google Scholar 

  37. Young P, Suter U (2003) The causes of Charcot-Marie-Tooth disease. Cell Mol Life Sci 60:2547–2560

    Article  PubMed  CAS  Google Scholar 

  38. Young P, Suter U (2001) Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Res Brain Res Rev 36:213–221

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Young, P. (2005). Medical treatment of hereditary neuropathies. In: Hereditary Peripheral Neuropathies. Steinkopff. https://doi.org/10.1007/3-7985-1586-7_13

Download citation

  • DOI: https://doi.org/10.1007/3-7985-1586-7_13

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1453-9

  • Online ISBN: 978-3-7985-1586-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation